18% GST Applicable On F-18 Drug Used For Cancer Diagnosis: AAR

Lucknow: The Uttar Pradesh Authority of Advance Ruling (AAR) has held that 18% GST is applicable on F-18 drugs used for cancer diagnosis.

The bench of Amit Kumar and Harilal Prajapati has observed that F18 is a radioisotope and fluorodeoxyglucose (18F-FDG) is a compound. The products being radioactive and compounds of the radioisotope 18F merit classification under heading 2844 only, although they satisfy the condition mentioned in Chapter 30, i.e., a diagnostic reagent designed to be administered to the patient.

The applicant is engaged in the manufacture of pioneer drugs labelled as  [18F]Fluorodeoxyglucose,  18F PSMA, 18F DOPA, and many more radioactive compounds labelled with F 18. F18 compounds are radioactive isotopes used as diagnostic reagents, primarily for the diagnosis of cancer. It is also used in cardiology and neurology. As per the applicant, the F18 is classifiable under chapter heading 3006 of the HSN, leviable to 12% GST, in terms of entry No 65 of Schedule II of the Notification No 01/2017-CT (Rate), dated June 28, 2017, read with the corresponding rate notification issued under the UPGST Act, 2017.

The applicant sought the advance ruling on the issue of whether the F-18 products would be classified under HSN 30063000, leviable to GST at the rate of 12%, in terms of entry no. 65 of Schedule 11 of Notification No. 01/2017-CT (Rate), dated June 28, 2017, issued under the CGST Act, 2017, read with the corresponding rate notification issued under the provisions of the UPGST Act, 2017, or not.

The appellant has submitted that the product in question, being diagnostic reagents to be administered to the patients, merits classification under heading 3006. “Opacifying preparations for X-ray examinations; diagnostic reagents designed to be administered to the patient.”.

The AAR has rejected the applicant’s classification under HSN 30063000 and imposed an 18% GST rate under HSN 2844. The decision is crucial for businesses dealing with radioactive compounds, setting a precedent for similar cases. The clarity provided by the AAR ensures a standardized approach to the classification of such products under the GST regime

Applicant’s Name: IBA Molecular Imaging (India) P. Ltd.

Related Posts

  • Pharma
  • February 5, 2025
  • 118 views
Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

A leading pharmaceutical powerhouse renowned for innovative skincare solutions has unveiled its latest breakthrough in tackling facial hyperpigmentation. The groundbreaking serum, featuring a first-of-its-kind dual liposomal technology in India, promises…

  • Pharma
  • February 5, 2025
  • 127 views
Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

New Delhi: With the aim of preventing unethical marketing and ensuring responsible promotion of pharmaceutical products by regulating interactions between doctors / registered medical practitioners (RMPs) and representatives of pharmaceutical…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

As Always Ahead of Game in healthcare, Doc was first to vote too

As Always Ahead of Game in healthcare, Doc was first to vote too

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Dabur reduces strategic review cycle to 3 years amidst short-term volatility, FMCG slowdown

Dabur reduces strategic review cycle to 3 years amidst short-term volatility, FMCG slowdown

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds